Literature DB >> 31414969

Inhibition of cancer metabolism: a patent landscape.

William P Katt1, Richard A Cerione1,2.   

Abstract

Cancer metabolism is currently a hot topic. Since it was first realized that cancer cells rely upon an altered metabolic program to sustain their rapid proliferation, the enzymes that support those metabolic changes have appeared to be good targets for pharmacological intervention. Here, we discuss efforts pertaining to targets in cancer metabolism, focusing upon the tricarboxylic acid cycle and the mechanisms which feed nutrients into it. We describe a broad landscape of small-molecule inhibitors, targeting a dozen different proteins, each implicated in cancer progression. We hope that this will serve as a reference both to the areas being most highly examined today and, relatedly, the areas that are still ripe for novel intervention.

Entities:  

Keywords:  TCA cycle; cancer; drug discovery; glutaminase; glutaminolysis; glycolysis; isocitrate dehydrogenase; metabolism; patents

Mesh:

Year:  2019        PMID: 31414969      PMCID: PMC6713032          DOI: 10.4155/ppa-2019-0012

Source DB:  PubMed          Journal:  Pharm Pat Anal        ISSN: 2046-8954


  45 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 2.  Anaplerotic molecules: current and future.

Authors:  Henri Brunengraber; Charles R Roe
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

Review 3.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Semin Cancer Biol       Date:  2008-12-03       Impact factor: 15.707

Review 4.  Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?

Authors:  Bryan C Fuchs; Barrie P Bode
Journal:  Semin Cancer Biol       Date:  2005-08       Impact factor: 15.707

Review 5.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

Review 6.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer.

Authors:  Maria L Macheda; Suzanne Rogers; James D Best
Journal:  J Cell Physiol       Date:  2005-03       Impact factor: 6.384

7.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

8.  Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).

Authors:  Mary M Robinson; Steven J McBryant; Takashi Tsukamoto; Camilo Rojas; Dana V Ferraris; Sean K Hamilton; Jeffrey C Hansen; Norman P Curthoys
Journal:  Biochem J       Date:  2007-09-15       Impact factor: 3.857

Review 9.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

10.  Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer.

Authors:  K Kaira; N Oriuchi; H Imai; K Shimizu; N Yanagitani; N Sunaga; T Hisada; S Tanaka; T Ishizuka; Y Kanai; H Endou; T Nakajima; M Mori
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

View more
  1 in total

Review 1.  Lactate dehydrogenase: a marker of diminished antitumor immunity.

Authors:  Sandra Van Wilpe; Rutger Koornstra; Martijn Den Brok; Jan Willem De Groot; Christian Blank; Jolanda De Vries; Winald Gerritsen; Niven Mehra
Journal:  Oncoimmunology       Date:  2020-02-26       Impact factor: 8.110

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.